BOSTON and MENLO PARK, Calif., Oct. 25, 2021 /PRNewswire/ -- Khosla
Ventures Acquisition Co. (Nasdaq:KVSA) ("KVSA"), a special purpose
acquisition company sponsored by an affiliate of Khosla Ventures,
LLC ("Khosla Ventures"), today announced that the Special Meeting
of Stockholders ("Special Meeting") to vote on the approval and
adoption of KVSA's business combination agreement with Valo
Health, LLC ("Valo Health") and the wholly owned subsidiary of Valo
Health, Valo Health, Inc. ("Valo"), will be held via live telecast
on November 16, 2021 at 10:00 a.m.
ET. Following the business combination, Valo will be a
wholly owned subsidiary of KVSA. Valo Health is a technology
company built to transform the drug discovery and development
process using human-centric data and artificial intelligence driven
computation.
Stockholders of record as of the close of business on
October 13, 2021 are entitled to vote at the Special Meeting.
The business combination, if approved by KVSA shareholders, is
expected to close as soon as practicable following the Special
Meeting. Upon the closing of the business combination, KVSA will
change its name to Valo Health Holdings, Inc. ("New Valo") and
New Valo shares are expected to trade on the New York Stock
Exchange under the ticker symbol "VH."
A definitive proxy statement and other relevant documents will
be mailed to stockholders of record of KVSA as of the close of
business on October 13, 2021. Stockholders are encouraged to
read the proxy statement and accompanying documents in their
entirety. Stockholders can also obtain free copies of the proxy
statement and all relevant documents filed or that will be filed
with the U.S Securities and Exchange Commission ("SEC") by KVSA
(when available) through the website maintained by the SEC at
http://www.sec.gov. The documents filed by KVSA with the SEC may
also be obtained free of charge at KVSA's website at
https://khoslaventuresacquisitionco.com/kvsa or by written
request to: Khosla Ventures Acquisition Co., 2128 Sand Hill Road,
Menlo Park, CA, 94025.
Stockholders of KVSA are encouraged to submit their vote as soon
as possible to ensure they are represented at the Special Meeting.
KVSA has engaged D.F. King & Co., Inc. ("DF King") as its
proxy solicitor in connection with the Special Meeting.
Stockholders needing assistance in voting their KVSA shares can
contact DF King by calling (800) 487-4870, or banks and brokers can
call collect at (212) 269-5550, or by emailing KVSA@dfking.com.
About Valo Health
Valo Health is a
technology company built to transform the drug discovery and
development process using human-centric data and artificial
intelligence driven computation. As a digitally native
company, Valo Health aims to fully integrate
human-centric data across the entire drug development lifecycle
into a single unified architecture, thereby accelerating the
discovery and development of life-changing drugs while
simultaneously reducing the cost, time, and failure rate. The
company's Opal Computational Platform™ consists of an
integrated set of capabilities designed to transform data into
valuable insights that may accelerate discoveries and
enable Valo Health to advance a robust pipeline of
programs across cardiovascular metabolic renal, oncology, and
neurodegenerative disease. Founded by Flagship
Pioneering and headquartered in Boston, MA, Valo Health also has
offices in Lexington, MA,
San Francisco, CA, Princeton, NJ, and in Branford, CT. To learn more,
visit www.valohealth.com.
About KVSA
KVSA is a special purpose acquisition
company sponsored by affiliates of Khosla Ventures. Khosla Ventures
manages a series of venture capital funds that make early-stage
venture capital investments and provide strategic advice to
entrepreneurs building companies with lasting significance. The
firm was founded in 2004 by Vinod
Khosla, co-founder of Sun Microsystems. Khosla Ventures has
over $14 billion dollars of assets under management and
focuses on a broad range of sectors including artificial
intelligence, agriculture/food, consumer, enterprise, financial
services, health, space, sustainable energy, robotics, VR/AR and 3D
printing. Collectively, Khosla Ventures portfolio of investments
has created nearly half a trillion dollars in market value.
Forward-Looking Statements
This communication
contains certain forward-looking statements within the meaning of
the federal securities laws with respect to the proposed
transaction between Valo, Valo Health and KVSA. These
forward-looking statements generally are identified by the words
"believe," "project," "expect," "anticipate," "estimate," "intend,"
"strategy," "future," "opportunity," "plan," "may," "should,"
"will," "would," "will be," "will continue," "will likely result,"
and similar expressions. Forward-looking statements are
predictions, projections and other statements about future events
that are based on current expectations and assumptions and, as a
result, are subject to risks and uncertainties. Many factors could
cause actual future events to differ materially from the
forward-looking statements in this communication. You should
carefully consider the risks and uncertainties described in the
"Risk Factors" section of KVSA's Annual Reports on Form 10-K,
Quarterly Reports on Form 10-Q, the registration statement on Form
S-4, and other documents filed by KVSA from time to time with the
SEC. These filings identify and address other important risks and
uncertainties that could cause actual events and results to differ
materially from those contained in the forward-looking statements.
Forward-looking statements speak only as of the date they are made.
Readers are cautioned not to put undue reliance on forward-looking
statements, and Valo, Valo Health and KVSA assume no
obligation and do not intend to update or revise these
forward-looking statements, whether as a result of new information,
future events, or otherwise. Neither Valo, Valo Health nor
KVSA gives any assurance that either Valo, Valo Health or KVSA will
achieve its expectations.
Additional Information and Where to Find It /
Non-Solicitation
In connection with the proposed
transaction, KVSA has filed, and the SEC has declared effective, a
Registration Statement on Form S-4 containing a proxy
statement/prospectus. The proxy statement/prospectus will be sent
to the stockholders of KVSA. KVSA also will file other documents
regarding the proposed transaction with the SEC. Before making any
voting decision, investors and security holders of KVSA are urged
to read the proxy statement/prospectus and all other relevant
documents filed or that will be filed with the SEC in connection
with the proposed transaction as they become available because they
will contain important information about the proposed transaction.
Investors and security holders will be able to obtain free copies
of the proxy statement/prospectus and all other relevant documents
filed or that will be filed with the SEC by KVSA through the
website maintained by the SEC at www.sec.gov.
Participants in Solicitation
KVSA, Valo and Valo
Health and their respective directors and executive officers may be
deemed to be participants in the solicitation of proxies from
KVSA's stockholders in connection with the proposed transaction.
Information about persons who may be deemed participants in the
solicitation is set forth in KVSA's filings with the SEC. To the
extent that holdings of KVSA's securities have changed since the
amounts printed in KVSA's Registration Statement on Form S-1, such
changes have been or will be reflected on Statements of Change in
Ownership on Form 4 filed with the SEC. A list of the names of such
directors and executive officers and information regarding their
interests in the business combination are contained in the proxy
statement/prospectus. You may obtain free copies of these documents
as described in the preceding paragraph.
No Offer or Solicitation
These communications do not
constitute an offer to sell or the solicitation of an offer to buy
any securities, or a solicitation of any vote or approval, nor
shall there be any sale of securities in any jurisdiction in which
such offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of any such
jurisdiction. No offering of securities shall be made except by
means of a prospectus meeting the requirements of Section 10
of the Securities Act, or an exemption therefrom.
View original
content:https://www.prnewswire.com/news-releases/khosla-ventures-acquisition-co-announces-special-meeting-of-stockholders-to-approve-business-combination-with-valo-health-301407794.html
SOURCE Khosla Ventures Acquisition Co.